European commission approves KEYTRUDA® (pembrolizumab) for patients with relapsed or refractory classical Hodgkin lymphoma who failed autologous stem cell transplant and brentuximab vedotin (BV), or who are transplant-ineligible and have failed BV

8th May 2017 Uncategorised 0

Merck

More: European commission approves KEYTRUDA® (pembrolizumab) for patients with relapsed or refractory classical Hodgkin lymphoma who failed autologous stem cell transplant and brentuximab vedotin (BV), or who are transplant-ineligible and have failed BV
Source: MDlinx